



February 13, 2026

**BSE Limited**  
Floor 25, P. J. Towers  
Dalal Street,  
**Mumbai - 400 001**

**The National Stock Exchange of India Limited**  
Exchange Plaza  
Bandra Kurla Complex, Bandra (E)  
**Mumbai - 400 051**

**Scrip Code: 530019**

**Symbol: JUBLPHARMA**

Dear Sirs,

In reference to our previous letter dated November 4, 2025, we are enclosing herewith an update with respect to USFDA Inspection at Contract manufacturing facility at Montreal, Canada communication in accordance with Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Date and Time of receipt - February 12, 2026, 10:08 AM (PST) i.e. February 12, 2026, 11:38 PM (IST).

We request you to take the same on record.

Thanking you,  
Yours faithfully,

For **Jubilant Pharmova Limited**

**Naresh Kapoor**  
**Company Secretary**  
Encl.: As above

A Jubilant Bhartia Company

OUR VALUES



**Jubilant Pharmova Limited**  
1-A, Sector 16-A,  
Noida-201 301, UP, India  
Tel: +91 120 4361000  
Fax: +91 120 4234895-96  
[www.jubilantpharmova.com](http://www.jubilantpharmova.com)

Regd Office:  
Bhartiagram, Gajraula  
Dist. Amroha - 244 223  
UP, India  
CIN : L24116UP1978PLC004624



**Jubilant Pharmova Limited**  
1A, Sector 16A, Noida – 201301, India  
Tel.: +91 120 4361000  
www.jubilantpharmova.com

## **USFDA Inspection Update - Contract manufacturing facility at Montreal, Canada**

**Noida, 13 Feb 2026**, Jubilant Pharmova Limited ('Company') today announced that Jubilant HollisterStier General Partnership ("JHSGP") has received a communication from the United States Food and Drug Administration (USFDA), in which the regulatory agency has determined the inspection classification for the Contract manufacturing facility at Montreal, Canada ("CMO Montreal") as "Official Action Indicated" (OAI). This is pursuant to the audit of CMO Montreal in the month of Oct & Nov'2025. The said audit was reported by the Company on 4th Nov 2025.

Since then, JHSGP has been working closely with USFDA and is committed to address the audit observations. Following the implementation of robust remediation measures, production operations have been resumed at the said facility in Q4'FY26.

JHSGP is jointly owned by subsidiaries of Jubilant Pharma Limited, a wholly owned subsidiary of the Company.

### **About Jubilant HollisterStier General Partnership (Canada)**

Jubilant HollisterStier General Partnership is a Canada based strategic alliance, jointly owned by subsidiaries of Jubilant Pharmova Limited, Jubilant HollisterStier Inc., Draxis Pharma LLC and 1359773 B.C. Unlimited Liability company. This partnership is key contributor to the company's global CDMO capabilities, offering contract manufacturing services for sterile products, including liquid and lyophilized injectables, ophthalmic solutions and sterile ointments.

### **About Jubilant Pharma Limited**

Jubilant Pharma Limited (JPL), a Company incorporated under the laws of Singapore and a wholly-owned subsidiary of Jubilant Pharmova Limited, is an integrated global pharmaceutical company engaged in manufacturing and supply of Radiopharmaceuticals with a network of 45 radio-pharmacies in the US, Allergy Immunotherapy, Contract Manufacturing of Sterile Injectables and Non-sterile products and Solid Dosage Formulations through multiple manufacturing facilities that cater to all the regulated market including USA, Europe and other geographies. The Company has a team of around 3,200 multicultural people across the globe and is committed to delivering value to its customers spread across over 75 countries. It is well recognized as a 'Partner of Choice' by leading pharmaceutical companies globally.

### **About Jubilant Pharmova Limited**

Jubilant Pharmova Limited (formerly Jubilant Life Sciences Limited) is a company with a global presence that is involved in Radiopharma, Allergy Immunotherapy, CDMO Sterile Injectables, Contract Research Development and Manufacturing Organisation (CRDMO), Generics and Proprietary Novel Drugs businesses. In the Radiopharma business, the Company is involved in the manufacturing and supply of Radiopharmaceuticals with a network of 45 radiopharmacies in the US. The Company's Allergy Immunotherapy business is involved in the manufacturing and supply of allergic extracts and venom products in the US and in some other markets such as Canada, Europe and Australia. Jubilant Pharmova Limited through its CDMO Sterile Injectables business offers manufacturing services including sterile fill and finish injectables (both liquid and lyophilization), full-service ophthalmic offer (liquids, ointments & creams) and ampoules. The CRDMO business of the Company includes the Drug Discovery Services business that provides contract research and development services through two world-class research centers in

---



Bengaluru and Noida in India and one in France. The CDMO-API business that is involved in the manufacturing of Active Pharmaceutical Ingredients. Jubilant Therapeutics is involved in the Proprietary Novel Drugs business and is an innovative biopharmaceutical company developing breakthrough therapies in the area of oncology and autoimmune disorders. The Company operates multiple manufacturing facilities that cater to all the regulated markets including USA, Europe and other geographies. Jubilant Pharmova Limited has a team of around 5,500 multicultural people across the globe. The Company is well recognized as a 'Partner of Choice' by leading pharmaceuticals companies globally. For more info, please visit [www.jubilantpharmova.com](http://www.jubilantpharmova.com)

### **For more information, please contact:**

#### **For Investors**

**Pankaj Dhawan**

Phone: +91 120 436 1105

E-mail: [Pankaj.dhawan@jubl.com](mailto:Pankaj.dhawan@jubl.com)

**Siddharth Rangnekar**

CDR India

Phone: +91 97699 19966

E-mail: [siddharth@cdr-india.com](mailto:siddharth@cdr-india.com)

#### **For Media**

**Sandipan Ghatak**

Phone: +91-98107 76182

E-mail: [sandipan.ghatak@jubl.com](mailto:sandipan.ghatak@jubl.com)

**Jyoti Sharma**

Ad Factors PR

Phone: +91 9810519900

E-mail: [jyoti.sharma@adfactorspr.com](mailto:jyoti.sharma@adfactorspr.com)

### **Disclaimer**

Statements in this document relating to future status, events, or circumstances, including but not limited to statements about plans and objectives, the progress and results of research and development, potential product characteristics and uses, product sales potential and target dates for product launch are forward-looking statements based on estimates and the anticipated effects of future events on current and developing circumstances. Such statements are subject to numerous risks and uncertainties and are not necessarily predictive of future results. Actual results may differ materially from those anticipated in the forward-looking statements. Jubilant Pharmova may, from time to time, make additional written and oral forward-looking statements, including statements contained in the company's filings with the regulatory bodies and its reports to shareholders. The company assumes no obligation to update forward-looking statements to reflect actual results, changed assumptions or other factors.

